Skip to main content
Onxeo logo

Onxeo — Investor Relations & Filings

Ticker · ALONX ISIN · FR0010095596 LEI · 96950018AS30IUG0V528 PA Manufacturing
Open in API
Filings indexed 661 across all filing types
Latest filing 2019-11-04 Regulatory Filings
Country FR France
Listing PA ALONX

About Onxeo

https://www.onxeo.com/

Valerio Therapeutics, formerly Onxeo, is a biotechnology company developing next-generation precision-guided therapies for complex and underserved diseases. The company's core technology is its proprietary V-Body platform, which is based on two fully synthetic single-domain antibody (sdAb) libraries. This platform is engineered to create advanced drug conjugates that enable deep tissue penetration and highly precise therapeutic delivery. By integrating innovative target identification, antibody engineering, and cutting-edge linker and payload technologies, Valerio Therapeutics aims to develop treatments with superior efficacy and target engagement. The company's strategy involves advancing its therapeutic candidates to key development milestones before pursuing strategic partnerships for co-development and out-licensing.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release from Onxeo S.A. dated November 4, 2019, announcing that it received a notice of grant from the USPTO for a new patent protecting the combination of AsiDNA™ with any PARP inhibitor for cancer treatment. The text focuses on intellectual property (patents), R&D progress (clinical studies planned), and company pipeline updates. This type of announcement, which details specific scientific or intellectual property developments rather than broad financial results (ER/IR) or management changes (MANG), is best classified as an Investor Presentation (IP) if it were a deck, or more generally, a communication aimed at investors regarding corporate development. Since it is a formal press release detailing a significant IP event and future clinical plans, it falls under the broad category of investor-focused material. Given the options, it is not a standard financial report (10-K, IR, ER), nor a specific regulatory filing like DIRS or DIV. It is a detailed update on corporate assets and strategy, making 'Investor Presentation' (IP) the closest fit for a substantive, non-financial-results-focused update, although 'Regulatory Filings' (RNS) is a possibility if it were purely a mandatory disclosure. However, the content is strategic and promotional regarding IP, aligning better with IP or potentially LTR if the patent was contested, but here it is a positive grant announcement. Given the focus on patent protection and future clinical strategy, 'Investor Presentation' (IP) is the most appropriate classification for this type of strategic corporate news release.
2019-11-04 French
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and announces that the company, Onxeo, has received funding (€495,000) from a French government program (Innov'up Leader PIA). It details the nature of the funding (grant and repayable advance) and its purpose (drug development). This type of announcement, which communicates a significant business event (funding/grant award) via a press release format, does not fit the specific definitions for 10-K, IR, ER, or CT. It is not a formal regulatory filing like a DVA or DIRS. Since it is a specific announcement about a business development (funding/financing), the most appropriate category is Capital/Financing Update (CAP). It is not a general regulatory filing (RNS) because CAP is more specific.
2019-10-17 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release dated October 17, 2019, announcing that Onxeo has been awarded a €495K financing grant from the French State and Île-de-France Region through the Innov'up Leader PIA program to develop an immuno-oncology drug candidate. This announcement details a specific corporate event related to funding and project development, which falls under financing activities. It is not a comprehensive annual report (10-K), an interim report (IR), an earnings release (ER), or a formal regulatory filing like a proxy statement. The most appropriate category for an announcement detailing fundraising, grants, or capital structure changes is 'Capital/Financing Update' (CAP). The document length (7964 chars) is substantial enough to be the primary announcement itself, not just a brief RPA.
2019-10-17 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release from Onxeo dated October 15, 2019, announcing that final results from its Phase 1 DRIIV-1 study of AsiDNA™ will be presented at an upcoming international cancer conference (AACR-NCI-EORTC). It details the positive findings regarding tolerance and activity, mentions the initiation of the next phase (DRIIV-1b), and provides a schedule of upcoming events, including the conference presentation. This content structure—announcing the presentation of clinical trial results and providing context/next steps—is characteristic of an Earnings Release (ER) or a general corporate update, but since it is focused on clinical data presentation rather than comprehensive financial performance for a period, it aligns best with an announcement of scientific/clinical progress. However, given the options, this is a specific corporate announcement about clinical data presentation, which often accompanies or precedes an Earnings Release, but is not the full financial report (10-K or IR). Since it is a formal announcement of key operational/clinical progress, and not a transcript (CT), a formal financial report (10-K/IR), or a proxy/governance document, it functions as an Earnings Release (ER) announcing key operational milestones, or potentially a Regulatory Filing (RNS) if it were less detailed. Given the level of detail about the study results and the context of presenting at a major conference, it functions as a significant corporate update, most closely matching the intent of an ER announcing operational/pipeline progress, or potentially an Investor Presentation (IP) if it were the slides themselves, but as a press release, ER is the closest fit for a major operational update.
2019-10-15 French
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is titled with an announcement: "Onxeo to Present Final Results of DRIIV-1 Phase 1 Study..." and contains quotes from the Medical Director, details about a poster presentation at a conference (AACR-NCI-EORTC), and a section titled 'Upcoming events'. The structure, tone, and content strongly indicate this is a press release announcing upcoming scientific data presentation and providing context on the study results. This type of announcement, which is not a full financial report (10-K, IR), a formal earnings release (ER), or a proxy statement, fits best under the general category for regulatory announcements or press releases that don't fit a more specific category. Since it is a press release announcing scientific/clinical updates, and not a formal financial filing, the most appropriate classification is Regulatory Filings (RNS) as a general announcement category, although it is highly specific scientific news. Given the options, RNS serves as the best fit for a general corporate/scientific press release that isn't explicitly an ER, CT, or IP.
2019-10-15 English
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is titled 'PRESS RELEASE' and announces that Onxeo received an 'EPO Intent-to-Grant Notice for New Patent'. It details the patent's scope, provides quotes from the CSO, lists upcoming events, and includes standard 'About Onxeo' and 'Forward looking statements' sections. This content is characteristic of a corporate announcement intended for immediate public disclosure regarding a significant business development (intellectual property/patent grant notification). Since it is a press release announcing a specific, non-financial event (patent notice) and does not appear to be a full regulatory report (like 10-K, IR, or ER), the most appropriate classification is Regulatory Filings (RNS), which serves as a general category for miscellaneous regulatory announcements that don't fit the highly specific financial/governance codes. It is not an Earnings Release (ER), Interim Report (IR), or a specific governance filing like DEF 14A or CGR.
2019-10-14 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.